| *Sponsored
Up Approx. 44% On Breaking News, (Nasdaq: RNAZ) Could Start Swelling With Breakout Buzz
May 1st Greetings, Friend!
TransCode Therapeutics, Inc. (Nasdaq: RNAZ) is bringing it early this morning.
Up approx. 44%, RNAZ is earning breakout buzz around the company's major announcement this morning.
Take a look:
TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer
- A total of 13 patients treated with four escalating doses of TTX-MC138
- No significant safety or dose limiting toxicities reported
- Two patients have so far maintained stable disease on treatment for at least seven months
- PD analysis at 24 hours post-dosing provides evidence of miR-10b target engagement
BOSTON, May 1, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced further progress in its Phase 1a clinical trial of TTX-MC138 in patients with metastatic cancer. TTX-MC138 is a first-in-class therapeutic candidate designed to inhibit microRNA-10b, or miR-10b, a microRNA widely believed to be critical to the emergence and progression of many metastatic cancers. To date, 13 patients have received at least one dose of TTX-MC138 at 4 separate dose levels ranging from 0.8 mg/kg to 4.8 mg/kg. Two patients have been treated in the expanded enrollment.
...
The observed tolerability profile and the available PK/PD results thus far supports advancement of the clinical trial to further evaluate safety and potential anti-tumor activity of TTX-MC138 in the planned dose expansion (Phase 1b) portion of the trial. At the highest dose administered, TTX-MC138 was well tolerated with no significant toxicities noted.
Read the full article here.
This news could start turning heads all over the market today!
Grab a quick look at the report below if you haven't done so yet and consider (Nasdaq: RNAZ) for your radar quickly. -----
Time for a quick review...
Catch Wednesday's breakout idea? From a previous day's close of $5.58, it scooted approx. $2.50+ short term to a high of $8.11 on hump day.
Tallying it up, the major move resulted in a run of approximately 47% short term!
Here's the thing. If you're new, or just plane forgot, that runner gives us two champs in a row.
Running for an after hours close of $3.50 this past Friday, that profile popped to a high of $4.4299 Monday for a solid surge of approximately 26%.
And now, I want to bring you another explosive idea.
From a mid-month low of April 17th, this Nasdaq profile has been on a heater, running approx. 127% in less than 2 weeks from a low of $.2196 to a high of $.5004.
Add 4 key potential catalysts into the mix, including a low float and an analyst $10 target suggesting over 2,000% potential upside, and there's no doubt why this breakout idea is atop my immediate watchlist.
Consider taking a look at: TransCode Therapeutics, Inc. (Nasdaq: RNAZ)
TransCode is a clinical-stage oncology company focused on treating metastatic disease.
The Company is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform.
The Company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis.
In addition, TransCode has a portfolio of other first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.
Lead Therapeutic Candidate - TTX-MC138
Targeting microRNA-10b - master regulator of metastasis
TransCode’s lead therapeutic candidate, TTX-MC138, is a targeted therapy designed to treat cancer patients with metastatic cancer, an area traditionally overlooked because, from a therapeutic perspective, non-metastatic and metastatic tumor cells are often viewed as being the same.
However, despite significant efforts made in the past several years to decipher the genetic structure of primary tumors, there has been relatively limited attention given to comprehending the genetic makeup of metastatic tumors.
- Small, non-coding strands of RNA (microRNAs) have been identified as a significant player in the pathology of cancer and metastasis
- The company's research observed that miRNA-10b acts as a master regulator of the viability of metastatic tumor cells
- miRNA-10b is shown to be largely dispensable for normal development but critical to tumorigenesis
- TransCode's competitive advantage derives from years of work to deliver oligonucleotides (synthetic RNA) to cancer cells, a decades long challenge in the market
- The iron oxide nanoparticle delivery platform, TTX, is highly tunable to pre-designed specifications to deliver therapeutic candidates to targets in tumors and metastases
- Treatment with TTX-MC138 has led to durable regression of established metastases in murine models of metastatic breast cancer and pancreatic cancer
- miRNA-10b has been shown to have broad applicability across over 18+ cancer types including breast, pancreatic, ovarian and colon cancer, glioblastomas and others
- TTX-MC138 is hormone receptor independent and has the potential to treat metastatic breast cancer regardless of type (ER+/-, PR+/, HER2+/-, or combinations thereof)
TransCode's promising therapeutic strategy relies on specific eradication of metastatic tumor cells– cells that have evolved from the primary tumor to escape into the circulation, survive during transit, and colonize distant organs.
TTX-MC138, their lead therapeutic candidate, has been shown to inhibit microRNA-10b resulting in regression of disease without recurrence in pre-clinical studies.
Check Sources And More Here: RNAZ Website. -----
These 4 Potential Catalysts Could Create A Breakout Spark For (Nasdaq: RNAZ)
#1. Low Float Volatility Potential: TransCode Therapeutics’ low float (fewer than 21Mn shares) could create a volatile environment at the drop of a hat.
#2. Initial Dosing Milestone: The company has begun initial dosing in the fourth cohort of its Phase 1 TTX-MC138 trial, marking key clinical progress.
#3. Safety Committee Approval: Safety Review Committee sign-off to open Cohort 4, following positive safety data, enables continued patient enrollment and trial momentum.
#4. Analyst Price Target: An analyst $10 price target indicates room for significant upside potential as new clinical or regulatory milestones are reached. -----
Coverage is officially initiated on TransCode Therapeutics, Inc. (Nasdaq: RNAZ).
I'll be in touch with updates as the week moves forward. Talk again soon.
All the best, Dane James Editor Market Pulse Today
(Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.)
*MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.
Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 04/30/2025 and ending on 05/01/2025 to publicly disseminate information about (RNAZ:US) via digital communications. Under this agreement, Thousand Sun Media LLC has been paid five thousand USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (RNAZ:US).
Please see important disclosure information here: https://marketpulsetoday.com/disclosure/rnaz-8m3bh/#details | 
